CMHC Faculty Members

Faculty of Tarsus Medical Group are leaders in healthcare

No data was found

Shamir R. Mehta, MD, MSc, FRCPS, FACC

Hamilton, Canada

Shamir R. Mehta, MD, MSc, FRCPS, FACC

Interventional Cardiologist


Dr. Shamir Mehta, MD, MSc, FRCPS, FACC, is the Douglas Holder Endowed Chair in Interventional Cardiology and a Professor of Medicine at McMaster University. He is Director of the Interventional Cardiology program at Hamilton Health Sciences and Senior Scientist at the Population Health Research Institute in Hamilton, Canada.

He has a busy interventional and structural cardiology practice and leads the percutaneous mitral and tricuspid valve programs at HHS. He co-chairs the Canadian Cardiovascular Society Antiplatelet Therapy Guidelines. As program director of interventional cardiology, he has supervised the training over 30 interventional cardiologists in Canada and globally. His research focuses on the role of percutaneous invasive therapies in patients with acute ischemic heart disease, and the evaluation of novel antithrombotic therapies and structural heart interventions.

Education and Training

He graduated from the University of Toronto’s Faculty of Medicine where he also completed internal medicine and cardiology training, followed by an interventional cardiology fellowship at the University Health Network.  He completed a research fellowship and Master’s in Health Research Methodology at McMaster University and received a CIHR New Investigator Award. He was named one of Canada’s Top 40 Under 40.

Professional Highlights

Dr. Mehta has published over 230 articles and holds peer-review operating grants from the CIHR, Heart and Stroke Foundation of Canada and industry.  He has led large-scale trials evaluating antiplatelet therapy in patients with acute coronary syndromes, having been the Principal Investigator of the PCI-CURE study establishing the benefit of clopidogrel in patients with ACS undergoing PCI and the 25,000 patient CURRENT-OASIS 7 trial evaluating aspirin and clopidogrel dosing. He is the Principal Investigator of PREMISE, a Canadian multicenter registry of patients undergoing percutaneous mitral valve repair with the Mitraclip. He has also led landmark trials evaluating pragmatic interventions in ACS, including RIVAL, establishing the benefit of a radial artery versus femoral artery approach in patients with ACS, TIMACS evaluating optimal timing of invasive intervention in patients with ACS and the recently published COMPELTE trial evaluating a strategy of complete revascularization in patients with STEMI and multivessel disease.  The COMPLETE trial was recognized by the editors of the New England Journal of Medicine as one of its Most Notable Articles of 2019.


Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.